Growth factor-mediated terminal differentiation of chronic myeloid leukemia

Atul Bedi, Constance A. Griffin, James P. Barber, Milada S. Vala, Anita L. Hawkins, Saul J. Sharkis, Barbara A. Zehnbauer, Richard J Jones

Research output: Contribution to journalArticle

Abstract

Expression of the BCR-ABL chimeric gene in chronic myeloid leukemia results in the inhibition of apoptosis, a genetically programmed process of autonomous cell death. BCR-ABL and other genetic factors that suppress apoptosis confer cross-resistance to cytotoxic agents with diverse mechanisms of action. Eradication of the chronic myeloid leukemia clone requires strategies that circumvent this inherent resistance to cytotoxic therapy. We have determined that BCR-ABL expression augments the sensitivity of hematopoietic cells to growth factor-mediated signals of differentiation; hematopoietic growth factors induce the selective terminal differentiation of chronic myeloid leukemia progenitors at concentrations that allow optimal growth of normal progenitors. Hematopoietic growth factors may be an effective strategy for the elimination of cytotoxic therapy-resistant leukemic cells by inducing their terminal differentiation while allowing concomitant expansion of coexistent normal hematopoietic progenitors.

Original languageEnglish (US)
Pages (from-to)5535-5538
Number of pages4
JournalCancer Research
Volume54
Issue number21
StatePublished - Nov 1 1994

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intercellular Signaling Peptides and Proteins
Hematopoietic Cell Growth Factors
Apoptosis
Cytotoxins
Cell Death
Clone Cells
Therapeutics
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bedi, A., Griffin, C. A., Barber, J. P., Vala, M. S., Hawkins, A. L., Sharkis, S. J., ... Jones, R. J. (1994). Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Research, 54(21), 5535-5538.

Growth factor-mediated terminal differentiation of chronic myeloid leukemia. / Bedi, Atul; Griffin, Constance A.; Barber, James P.; Vala, Milada S.; Hawkins, Anita L.; Sharkis, Saul J.; Zehnbauer, Barbara A.; Jones, Richard J.

In: Cancer Research, Vol. 54, No. 21, 01.11.1994, p. 5535-5538.

Research output: Contribution to journalArticle

Bedi, A, Griffin, CA, Barber, JP, Vala, MS, Hawkins, AL, Sharkis, SJ, Zehnbauer, BA & Jones, RJ 1994, 'Growth factor-mediated terminal differentiation of chronic myeloid leukemia', Cancer Research, vol. 54, no. 21, pp. 5535-5538.
Bedi A, Griffin CA, Barber JP, Vala MS, Hawkins AL, Sharkis SJ et al. Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Research. 1994 Nov 1;54(21):5535-5538.
Bedi, Atul ; Griffin, Constance A. ; Barber, James P. ; Vala, Milada S. ; Hawkins, Anita L. ; Sharkis, Saul J. ; Zehnbauer, Barbara A. ; Jones, Richard J. / Growth factor-mediated terminal differentiation of chronic myeloid leukemia. In: Cancer Research. 1994 ; Vol. 54, No. 21. pp. 5535-5538.
@article{2d2597764ab04978bf64cf3b1a0cae10,
title = "Growth factor-mediated terminal differentiation of chronic myeloid leukemia",
abstract = "Expression of the BCR-ABL chimeric gene in chronic myeloid leukemia results in the inhibition of apoptosis, a genetically programmed process of autonomous cell death. BCR-ABL and other genetic factors that suppress apoptosis confer cross-resistance to cytotoxic agents with diverse mechanisms of action. Eradication of the chronic myeloid leukemia clone requires strategies that circumvent this inherent resistance to cytotoxic therapy. We have determined that BCR-ABL expression augments the sensitivity of hematopoietic cells to growth factor-mediated signals of differentiation; hematopoietic growth factors induce the selective terminal differentiation of chronic myeloid leukemia progenitors at concentrations that allow optimal growth of normal progenitors. Hematopoietic growth factors may be an effective strategy for the elimination of cytotoxic therapy-resistant leukemic cells by inducing their terminal differentiation while allowing concomitant expansion of coexistent normal hematopoietic progenitors.",
author = "Atul Bedi and Griffin, {Constance A.} and Barber, {James P.} and Vala, {Milada S.} and Hawkins, {Anita L.} and Sharkis, {Saul J.} and Zehnbauer, {Barbara A.} and Jones, {Richard J}",
year = "1994",
month = "11",
day = "1",
language = "English (US)",
volume = "54",
pages = "5535--5538",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Growth factor-mediated terminal differentiation of chronic myeloid leukemia

AU - Bedi, Atul

AU - Griffin, Constance A.

AU - Barber, James P.

AU - Vala, Milada S.

AU - Hawkins, Anita L.

AU - Sharkis, Saul J.

AU - Zehnbauer, Barbara A.

AU - Jones, Richard J

PY - 1994/11/1

Y1 - 1994/11/1

N2 - Expression of the BCR-ABL chimeric gene in chronic myeloid leukemia results in the inhibition of apoptosis, a genetically programmed process of autonomous cell death. BCR-ABL and other genetic factors that suppress apoptosis confer cross-resistance to cytotoxic agents with diverse mechanisms of action. Eradication of the chronic myeloid leukemia clone requires strategies that circumvent this inherent resistance to cytotoxic therapy. We have determined that BCR-ABL expression augments the sensitivity of hematopoietic cells to growth factor-mediated signals of differentiation; hematopoietic growth factors induce the selective terminal differentiation of chronic myeloid leukemia progenitors at concentrations that allow optimal growth of normal progenitors. Hematopoietic growth factors may be an effective strategy for the elimination of cytotoxic therapy-resistant leukemic cells by inducing their terminal differentiation while allowing concomitant expansion of coexistent normal hematopoietic progenitors.

AB - Expression of the BCR-ABL chimeric gene in chronic myeloid leukemia results in the inhibition of apoptosis, a genetically programmed process of autonomous cell death. BCR-ABL and other genetic factors that suppress apoptosis confer cross-resistance to cytotoxic agents with diverse mechanisms of action. Eradication of the chronic myeloid leukemia clone requires strategies that circumvent this inherent resistance to cytotoxic therapy. We have determined that BCR-ABL expression augments the sensitivity of hematopoietic cells to growth factor-mediated signals of differentiation; hematopoietic growth factors induce the selective terminal differentiation of chronic myeloid leukemia progenitors at concentrations that allow optimal growth of normal progenitors. Hematopoietic growth factors may be an effective strategy for the elimination of cytotoxic therapy-resistant leukemic cells by inducing their terminal differentiation while allowing concomitant expansion of coexistent normal hematopoietic progenitors.

UR - http://www.scopus.com/inward/record.url?scp=0027942768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027942768&partnerID=8YFLogxK

M3 - Article

C2 - 7923192

AN - SCOPUS:0027942768

VL - 54

SP - 5535

EP - 5538

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -